多発性骨髄腫治療薬の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Multiple Myeloma Drugs Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease

PART 06: Pipeline analysis

PART 07: Market landscape
• Global multiple myeloma drugs market
• Five forces analysis

PART 08: Market segmentation by therapy
• Targeted therapy
• Biologic therapy
• Chemotherapy
• Others

PART 09: Geographical segmentation
• Multiple myeloma drugs market in Americas
• Multiple myeloma drugs market in EMEA
• Multiple myeloma drugs market in APAC

PART 10: Market drivers
• Growing demand for biologic therapies
• Paradigm shift toward the adoption of novel proteasome inhibitors
• Presence of large patient pool

PART 11: Impact of drivers

PART 12: Market challenges
• Growing popularity of complementary and alternative medicines (CAM)
• High costs affecting the adoption rates of multiple myeloma drugs
• Adverse effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Emergence of nanomedicine platform
• Advent of microRNA therapeutics
• Increasing inorganic growth strategies

PART 15: Vendor landscape
• Competitive scenario

PART 16: Key vendor analysis
• Amgen
• Celgene
• Johnson & Johnson
• Novartis
• Takeda Pharmaceuticals
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Key customer segments of global multiple myeloma drugs market
Exhibit 03: Factors affecting the adoption rates of multiple myeloma drugs market
Exhibit 04: Pipeline landscape
Exhibit 05: Pipeline analysis
Exhibit 06: Global multiple myeloma drugs market snapshot
Exhibit 07: Global multiple myeloma drugs market 2016-2021 ($ billions)
Exhibit 08: Opportunity analysis of global multiple myeloma drugs market
Exhibit 09: Opportunity analysis in developed and emerging markets
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global multiple myeloma drugs market by therapy 2016
Exhibit 12: Lifecycle analysis of segments in global multiple myeloma drugs market 2016
Exhibit 13: Segmentation of global multiple myeloma drugs market based on geography 2016 and 2021
Exhibit 14: Multiple myeloma drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 15: Market scenario in Americas
Exhibit 16: Multiple myeloma drugs market in Americas 2016-2021 ($ billions)
Exhibit 17: Market scenario in EMEA
Exhibit 18: Multiple myeloma drugs market in EMEA 2016-2021 ($ billions)
Exhibit 19: Market scenario in APAC
Exhibit 20: Multiple myeloma drugs market in APAC 2016-2021 ($ billions)
Exhibit 21: Key drivers and challenges in APAC
Exhibit 22: Impact of drivers
Exhibit 23: Alternative therapies for multiple myeloma drugs
Exhibit 24: Forcefield analysis of drivers and challenges
Exhibit 25: Impact of drivers and challenges
Exhibit 26: Key factors driving the adoption of nanomedicine
Exhibit 27: Factors driving the adoption of miRNA therapeutics
Exhibit 28: Key deals in global multiple myeloma drugs market
Exhibit 29: Competitive structure analysis of global multiple myeloma drugs market 2015
Exhibit 30: Market share analysis in global multiple myeloma drugs market
Exhibit 31: Competitive analysis of global multiple myeloma drugs market
Exhibit 32: Market penetration of various multiple myeloma drugs manufacturers worldwide (2016)
Exhibit 33: Amgen: Key highlights
Exhibit 34: Amgen: Strength assessment
Exhibit 35: Amgen: Strategy assessment
Exhibit 36: Amgen: Opportunity assessment
Exhibit 37: Celgene: Key highlights
Exhibit 38: Celgene: Strength assessment
Exhibit 39: Celgene: Strategy assessment
Exhibit 40: Celgene: Opportunity assessment
Exhibit 41: Celgene: YoY revenue and growth rate of REVLIMID 2013-2015 ($ billions)
Exhibit 42: Celgene: YoY revenue and growth rate of POMALYST 2013-2015 ($ millions)
Exhibit 43: Celgene: YoY revenue and growth rate of THALOMID 2013-2015 ($ millions)
Exhibit 44: Johnson & Johnson: Key highlights
Exhibit 45: Johnson & Johnson: Strength assessment
Exhibit 46: Johnson & Johnson: Strategy assessment
Exhibit 47: Johnson & Johnson: Opportunity assessment
Exhibit 48: Johnson & Johnson: YoY global revenue comparison of VELCADE 2013-2015 ($ billions)
Exhibit 49: Novartis: Key highlights
Exhibit 50: Novartis: Strength assessment
Exhibit 51: Novartis: Strategy assessment
Exhibit 52: Novartis: Opportunity assessment
Exhibit 53: Takeda Pharmaceuticals: Key highlights
Exhibit 54: Takeda Pharmaceuticals: Strength assessment
Exhibit 55: Takeda Pharmaceuticals: Strategy assessment
Exhibit 56: Takeda Pharmaceuticals: Opportunity assessment


【レポート販売概要】

■ タイトル:多発性骨髄腫治療薬の世界市場2017-2021
■ 英文:Global Multiple Myeloma Drugs Market 2017-2021
■ 発行日:2016年12月27日
■ 調査会社:Technavio
■ 商品コード:IRTNTR11277
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。